Who Exports Gemcitabine from India — 248 Suppliers Behind a $46.5M Market
India's gemcitabine export market is supplied by 248 active exporters who collectively shipped $46.5M across 2,938 shipments. FRESENIUS KABI ONCOLOGY LIMITED leads with a 14.8% market share, followed by EUGIA PHARMA SPECIALITIES LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED. The top 5 suppliers together control 55.8% of total export value, reflecting a moderately competitive market structure.
Top Gemcitabine Exporters from India — Ranked by Export Value
FRESENIUS KABI ONCOLOGY LIMITED is the leading gemcitabine exporter from India, holding a 14.8% share of the $46.5M market across 2,938 shipments from 248 exporters. The top 5 suppliers — FRESENIUS KABI ONCOLOGY LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, MYLAN LABORATORIES LIMITED, INTAS PHARMACEUTICALS LIMITED — collectively control 55.8% of total export value, indicating a moderately concentrated market. Individual shares are: FRESENIUS KABI ONCOLOGY LIMITED (14.8%), EUGIA PHARMA SPECIALITIES LIMITED (12.7%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (12.5%), MYLAN LABORATORIES LIMITED (8.0%), INTAS PHARMACEUTICALS LIMITED (7.9%).
Top Gemcitabine Exporters from India
Ranked by export value · 248 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | FRESENIUS KABI ONCOLOGY LIMITED GEMCITABINEGEMCITABINE FRESENIUSINJ.1GGEMCITABINE KABI INJ. 1000MG/26.3ML VIALGEMITA USP INJ. 1.4GM/VI | $6.9M | 20 | 14.8% |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED GEMCITABINE CONCENTRATED SOLUTION FOR IN | $5.9M | 2 | 12.7% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES LIMITED ONGECIN 1000 TENDER GEMCITABINE FOR INJECTION USP 1000 MGGEMCITABINE INJ.2G-BR-H000205209GEMCITABINE SUN PPF1200MG/120ML1S PU IT | $5.8M | 3 | 12.5% |
| 4 | MYLAN LABORATORIES LIMITED GEMCITABINE INJECTION 2G US-F000206913GEMCITABINE INJ 38MG/ML 26.3ML 1S MYL USGEMCITABINE INJ. 1G US N+ F000206904 | $3.7M | 1 | 8.0% |
| 5 | INTAS PHARMACEUTICALS LIMITED GEMCITABINE CONCENTRATED SOLUTION FOR INGEMCITABINE INJECTION 2G US-F000206913GEMCITABINE INJ 38MG/ML 26.3ML 1S MYL US | $3.7M | 17 | 7.9% |
| 6 | ACCURE LABS PRIVATE LIMITED ONGECIN 1000 (GEMCITABINE FOR INJECTIONONGECIN 1000ONGECIN 1000 TENDER GEMCITABINE FOR INJECTION USP 1000 MG | $3.1M | 2 | 6.7% |
| 7 | JODAS EXPOIM PRIVATE LIMITED GEMCITABINE LYOPHILIZATE FOR PREPARATION | $2.8M | 2 | 6.0% |
| 8 | ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED GEMCITABINE INJECTION 2G US-F000206913GEMCITABINE INJ 38MG/ML 26.3ML 1S MYL USONGECIN 1000 (GEMCITABINE FOR INJECTION | $2.7M | 9 | 5.9% |
| 9 | VENUS REMEDIES LIMITED GEMCITABINE CONCENTRATED SOLUTION FOR INGEMCITABINE KABI INJ. 1000MG/26.3ML VIALCITABOL 1000 MG (GEMCITABINE POWDER FOR | $2.2M | 23 | 4.7% |
| 10 | ADLEY FORMULATIONS PRIVATE LIMITED ONGECIN 1000 (GEMCITABINE FOR INJECTIONONGECIN 1000 | $1.4M | 4 | 3.0% |
| 11 | NAPROD LIFE SCIENCES PRIVATE LIMITED GEMCITABINEGEMCITABINE FRESENIUSINJ.1GPHARMA DRUGS & MEDI ACCORD -GEMCITABINEPHARMA DRUG&MED:ACCORD -GEMCITABINE 1G E | $1.1M | 13 | 2.4% |
| 12 | RR PHARMACEUTICALS PRIVATE LIMITED | $640.6K | 1 | 1.4% |
| 13 | INTAS PHARMACEUTICALS LTD GEMCITABINE CONCENTRATED SOLUTION FOR INGEMCITABINE INJECTION 2G US-F000206913GEMCITABINE INJ 38MG/ML 26.3ML 1S MYL US | $444.4K | 3 | 1.0% |
| 14 | GETWELL PHARMA INDIA PRIVATE LIMITED | $295.2K | 5 | 0.6% |
| 15 | UNITED BIOTECH PRIVATE LIMITED | $293.6K | 7 | 0.6% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Gemcitabine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| FRESENIUS KABI ONCOLOGY LIMITED | Approved | Yes | Yes | 1 | FDA approval for Bortezomib 3.5mg/vial on May 2, 2022. |
| MYLAN LABORATORIES LIMITED | Approved | Yes | Yes | Multiple | WHO prequalification for Dolutegravir 50mg tablet on October 31, 2018. |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | Approved | Yes | Yes | Multiple | FDA approval for Bosentan 62.5mg and 125mg tablets on April 26, 2019. |
| INTAS PHARMACEUTICALS LIMITED | Approved | Yes | Yes | Multiple | FDA approval for various generic drugs; specific details not found. |
| ZYDUS HOSPIRA ONCOLOGY PRIVATE LIMITED | Approved | Yes | Yes | Multiple | FDA approval for Bortezomib 3.5mg/vial on May 2, 2022. |
| VENUS REMEDIES LIMITED | Not Listed | Yes | Yes | None | WHO-GMP certification obtained; specific date not found. |
| NAPROD LIFE SCIENCES PRIVATE LIMITED | Not Listed | Yes | Yes | None | WHO-GMP certification obtained; specific date not found. |
| UNITED BIOTECH PRIVATE LIMITED | Not Listed | Yes | Yes | None | WHO-GMP certification obtained; specific date not found. |
TransData Nexus reviewed the regulatory standing of 8 leading Gemcitabine exporters from India. 5 hold US FDA facility approvals, 8 maintain WHO-GMP certification, and 8 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Gemcitabine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," contributes approximately 40% of the country's bulk drug production. The city hosts over 2,000 pharmaceutical companies, including major players such as Dr. Reddy's Laboratories, Aurobindo Pharma, and Natco Pharma. The establishment of Genome Valley, a premier biotech cluster, has further solidified Hyderabad's position as a hub for pharmaceutical research and manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Gujarat accounts for 33% of India's drug manufacturing and 28% of drug exports, with Ahmedabad and Vadodara being central to this output. The region is home to prominent companies such as Alembic Pharmaceuticals, Sun Pharmaceutical Industries, and Zydus Cadila Healthcare. Vadodara, in particular, has a rich history in pharmaceuticals, with Alembic Pharmaceuticals established there in 1907.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical industry. Mumbai, being a major port city, facilitates the export of pharmaceutical products to global markets. The region hosts several pharmaceutical giants, including Sun Pharmaceutical Industries and Lupin Limited, which leverage the strategic location for efficient distribution and export operations.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical hub, primarily due to favorable tax incentives offered by the government. This zone attracts numerous pharmaceutical companies seeking cost-effective manufacturing solutions, thereby contributing substantially to India's pharmaceutical production capacity.
5Sourcing Recommendations
- Diversify Supplier Base: To mitigate risks associated with over-reliance on a limited number of suppliers, consider engaging with multiple manufacturers across different clusters.
- Evaluate Supplier Capabilities: Assess the technical capabilities and compliance records of potential suppliers, especially those in Hyderabad and Ahmedabad-Vadodara, to ensure consistent quality and regulatory adherence.
- Leverage Export Hubs: Utilize the logistical advantages of the Mumbai-Thane-Raigad region to streamline export processes and reduce lead times.
- Consider Cost Benefits: Explore manufacturing options in the Baddi-Nalagarh tax incentive zone to capitalize on potential cost savings without compromising on quality.
By strategically sourcing from these diverse pharmaceutical clusters, companies can enhance supply chain resilience and optimize operational efficiencies.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Gemcitabine exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for targeted oncology expansion
In May 2025, Sun Pharmaceutical Industries Limited completed its acquisition of Checkpoint Therapeutics, Inc., an immunotherapy and targeted oncology company, for USD 4.10 per share, with additional contingent value rights of up to USD 0.70 per share. The acquisition includes Unloxcyttm, the first FDA-approved anti-PD-L1 therapy for advanced cutaneous squamous cell carcinoma. - IMPACT: This acquisition strengthens Sun Pharma’s specialty oncology portfolio, potentially enhancing its Gemcitabine export capabilities.
Impact: This acquisition strengthens Sun Pharma’s specialty oncology portfolio, potentially enhancing its Gemcitabine export capabilities.
Intas Pharmaceuticals Limited — Accord Plasma (Intas) acquires Prothya Biosolutions
Accord Plasma, a subsidiary of Intas Pharmaceuticals, completed the acquisition of Prothya Biosolutions Belgium BV and its subsidiaries. The deal adds Prothya’s European plasma fractionation facilities and collection network to Accord’s global plasma manufacturing footprint, expanding production and access to plasma-derived medicines. - IMPACT: This acquisition enhances Intas Pharmaceuticals' manufacturing capabilities, which may positively influence its Gemcitabine export operations.
Impact: This acquisition enhances Intas Pharmaceuticals' manufacturing capabilities, which may positively influence its Gemcitabine export operations.
Eugia Pharma Specialities Limited — Eugia Pharma receives USFDA approval for Everolimus Tablets
Eugia Pharma Specialities Limited, a wholly owned subsidiary of Aurobindo Pharma Limited, received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Everolimus Tablets, 0.25 mg, 0.5 mg, 0.75 mg, and 1 mg. The product is expected to be launched in Q1FY27. - IMPACT: This regulatory approval may bolster Eugia Pharma's oncology portfolio, potentially affecting its Gemcitabine export dynamics.
Impact: This regulatory approval may bolster Eugia Pharma's oncology portfolio, potentially affecting its Gemcitabine export dynamics.
Common Questions — Gemcitabine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which gemcitabine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, FRESENIUS KABI ONCOLOGY LIMITED leads with 339 recorded shipments worth $6.9M. EUGIA PHARMA SPECIALITIES LIMITED (188 shipments) and SUN PHARMACEUTICAL INDUSTRIES LIMITED (137 shipments) are also established high-volume exporters.
Q How many gemcitabine manufacturers are there in India?
India has 248 active gemcitabine exporters with a combined export market of $46.5M across 2,938 shipments to 125 countries. The top 5 suppliers hold 55.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for gemcitabine from India?
Average FOB unit price: $10.70 per unit, ranging from $0.03 to $2290.14. Average shipment value: $15.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 248 verified Indian exporters of Gemcitabine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,938 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 125 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,938 Verified Shipments
248 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists